格隆汇9月1日丨国富量子(00290.HK)公布，公司的股份(证券代号：00290)将于今天(1/9/2025)下午一时 正起恢复买卖。 ...

此外，公司已向联交所申请自2025年9月1日下午一时正起恢复公司股份买卖。 格隆汇9月1日丨国富量子(00290.HK)公布，公司获公司单一最大股东柳志伟及股东王涛分别告知，于 2025年9月1日，柳志伟连同AI International Capital ManagementLtd.(由柳志伟全资拥有)、Caitex Technology Holdings Limited(由淳大国际资本管理有限公司全资拥有，而淳大国际资本管理有限公司由 柳志伟全资拥有)及王涛(统称"卖方")已与FINAL TOUCH LTD.("买方")订立买卖协议，有条件出售合共 18.48亿股公司股份，相当于公告日期本公司已发行股本总数约20.31%，代价为31.42亿港元。买方为联 交所上市公司华检医疗控股有限公司(股份代号：1931)("华检医疗")的全资附属公司。 紧随买卖协议完成后，柳志伟将直接及间接持有合共8832.8万股股份(约占公司已发行股本0.97%)，且不 再为公司之单一最大股东，王涛将直接持有9037.30万股股份(约占公司已发行股本0.99%)，而买方及其 最终控股公司华检医疗将持有公司18.48亿股股份(约占公 ...

（前稱 GoFintech Innovation Limited 國富創新有限公司） （於開曼群島註冊成立之有限公司） 網址：https://290.com.hk （股份代號：290） 內幕消息 單一最大股東變動 及 恢復買賣 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或 任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 GoFintech Quantum Innovation Limited 國富量子創新有限公司 陳健生 香港，二零二五年九月一日 本公告乃由國富量子創新有限公司（「本公司」）董事（「董事」）會（「董事會」）根據 香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第13.09條及香 港法例第571章證券及期貨條例第XIVA部之內幕消息條文（定義見上市規則）作出。 本公司獲本公司單一最大股東柳志偉博士（「柳博士」）及股東王濤先生（「王先生」） 分別告知，於二零二五年九月一日，柳博士連同AI International Capital Management Ltd.（由 ...

Core Viewpoint - Huajian Medical (01931) has seen a significant stock increase of over 13% following the announcement of a conditional agreement to acquire a 20.31% stake in Guofu Quantum for approximately HKD 3.142 billion, which will be paid through the issuance of shares. This acquisition aims to enhance capital synergy and establish an innovative cooperative network to support the globalization of Chinese assets [1][2]. Group 1 - Huajian Medical's stock rose by 13.31% to HKD 10.98, with a trading volume of HKD 45.6534 million [1]. - The acquisition of Guofu Quantum will make Huajian Medical the major shareholder, aiming to strengthen capital collaboration and broaden institutional cooperation [1]. - The company has launched several strategic initiatives since late July, including the "NewCo+RWA" exchange strategy and the issuance of IVDD stablecoins [2]. Group 2 - Huajian Medical's U.S. subsidiary is pursuing a stablecoin license, and the company has partnered with BGI's Huada Gongying to establish the world's first "innovative drug intellectual property tokenization fund" [2]. - The company announced the initiation of a "global enhanced Ethereum (ETH) treasury" strategy and completed a compliant purchase of HKD 149 million in ETH [2]. - Huajian Medical is seeking shareholder approval for a HKD 3 billion ETH purchase authorization to support the ecosystem construction of the medical innovative drug RWA trading platform [2].

Group 1 - Huajian Medical (01931) shares rose over 13%, reaching 10.98 HKD with a trading volume of 45.65 million HKD [1] - The company announced a conditional agreement to acquire 20.31% of Guofu Quantum's shares for approximately 3.142 billion HKD, to be paid through the issuance of consideration shares [1] - This acquisition aims to enhance capital synergy, promote the implementation of RWA ecosystem, and build an innovative cooperation network to support the globalization of Chinese assets [1] Group 2 - Since late July, Huajian Medical has launched several key strategic initiatives, including the introduction of the "NewCo+RWA" exchange strategy and the issuance of IVDD stablecoins [2] - The company is pursuing a stablecoin license for its U.S. subsidiary and has partnered with BGI's subsidiary to establish the world's first "innovative drug intellectual property tokenization fund" [2] - On August 8, Huajian Medical initiated the "Global Enhanced Ethereum (ETH) Treasury" strategy, collaborating with licensed exchange HashKey and completing a compliant purchase of 149 million HKD in ETH [2] - The company is seeking shareholder approval for a 3 billion HKD ETH purchase authorization to provide value anchoring and revenue feedback mechanisms for the RWA trading platform [2]

Group 1: Transaction Details - On September 1, 2025, Huajian Medical announced the acquisition of a 20.31% stake in Guofu Quantum for HKD 3.142 billion, becoming the controlling shareholder of the quantum technology company [1][2] - The acquisition involves the issuance of approximately 324 million shares at a price of about HKD 9.69 per share [2] Group 2: Strategic Synergy - The acquisition represents a strategic collaboration between Huajian Medical and Guofu Quantum, enhancing Huajian's capabilities in the digital asset and RWA sectors [6][7] - Huajian Medical aims to create a complete ecosystem for the tokenization of medical innovation assets and high-tech assets of publicly listed companies [8][9] Group 3: Market Context and Growth Potential - The RWA trading platform developed by Huajian Medical is designed to improve liquidity and reduce financing costs for high-value medical assets, which are characterized by long development cycles and low liquidity [9] - The total transaction amount for innovative drugs in China reached USD 60.8 billion in the first half of 2025, reflecting a 129% year-on-year increase, indicating growing recognition of Chinese innovative drug assets in the global market [9] Group 4: Policy Support - The strategic layout of Huajian Medical and Guofu Quantum aligns with national policy directions aimed at promoting the global market development of innovative drugs [10] - Recent regulatory advancements in Hong Kong regarding stablecoins and digital assets provide a favorable environment for the development of RWA business [10] Group 5: Challenges and Future Outlook - Despite the promising outlook for RWA, challenges such as liquidity issues and regulatory complexities remain [11] - The RWA industry is transitioning from concept validation to large-scale application, with a total locked value (TVL) reaching USD 12.5 billion as of June 2025, indicating significant growth potential [12]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或 任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 短暫停牌 應國富量子創新有限公司（「本公司」要求，本公司股份自二零二五年九月一日上 午九時十八分起在香港聯合交易所有限公司短暫停牌，以待刊發載有本公司內幕 消息之公告。 GoFintech Quantum Innovation Limited 國富量子創新有限公司 （前稱 GoFintech Innovation Limited 國富創新有限公司） （於開曼群島註冊成立之有限公司） （股份代號：290） 網址：https://290.com.hk 承董事會命 國富量子創新有限公司 香港，二零二五年九月一日 於本公告日期，董事會包括一名執行董事孫青女士；三名非執行董事，分別為聶日 明博士、李春光先生及華暘先生；以及四名獨立非執行董事，分別為陳健生先生（主 席）、趙公直先生、雷美嘉女士及梁金祥博士。 主席兼獨立非執行董事 陳健生 ...

国富量子（00290）公布，公司股份已于2025年9月1日上午9点18分起短暂停止买卖。 来源：新浪港股 ...

Group 1 - The core point of the news is that Huajian Medical has acquired a 20.31% stake in Guofu Quantum for HKD 3.142 billion, becoming the controlling shareholder, which is a strategic move to build a global RWA tokenized digital trading platform [1][2][7] - The acquisition involves Huajian Medical's subsidiary issuing approximately 324 million shares at around HKD 9.69 per share to complete the purchase [2] - This acquisition is seen as a significant step for Huajian Medical, which has shifted from being a medical equipment distributor to actively pursuing blockchain strategies, including the establishment of the world's first RWA trading platform for innovative drug intellectual property [5][8] Group 2 - The strategic collaboration between Huajian Medical and Guofu Quantum is expected to create a complete ecosystem for the tokenization of medical innovation drug intellectual property and high-tech assets of publicly listed companies [8][9] - Guofu Quantum, holding multiple financial licenses, enhances Huajian Medical's capabilities in the digital asset and RWA sectors, while Huajian Medical provides financial support and resources from the medical industry [6][8] - The RWA trading platform developed by Huajian Medical aims to connect real-world assets with global capital, potentially positioning the company as a dominant player in the RWA sector, similar to Alibaba's role in connecting SMEs with global markets [9][10] Group 3 - The strategic initiatives align with national policies promoting the global market development of innovative drugs, supported by recent regulatory advancements in digital asset management in Hong Kong and the U.S. [10] - The RWA market is experiencing significant growth, with a total locked value (TVL) reaching USD 12.5 billion by mid-2025, indicating a strong upward trend in asset tokenization [12] - Despite the promising outlook, challenges such as liquidity issues and regulatory complexities remain critical factors for the RWA market's development [11]

Group 1 - The core point of the article is that Huajian Medical plans to acquire a 20.31% stake in Guofu Quantum for approximately HKD 3.142 billion, which will be paid through the issuance of 324 million shares at HKD 9.69 per share, making Huajian Medical the controlling shareholder of Guofu Quantum after the acquisition [1] - Guofu Quantum is a comprehensive technology financial platform based in Hong Kong, leveraging the Greater Bay Area and aiming for international reach, with significant resources in quantum computing, artificial intelligence, and blockchain integration [1] - The acquisition is a crucial step for Huajian Medical to advance its RWA exchange strategy and achieve ecological synergy, holding significant industrial and capital value [1] Group 2 - After the acquisition, Huajian Medical will utilize Guofu Quantum's 22.5% stake in Southern Dongying to collaboratively build a blockchain and fintech-centric on-chain financial ecosystem [2] - This platform aims to deeply integrate compliant digital architecture with traditional asset forms, promoting the tokenization, fragmentation, and cross-border flow of assets, thereby creating an efficient, transparent, and interconnected new financial infrastructure [2] - The focus will be on promoting high-quality Chinese assets to go "on-chain" and "overseas" in a compliant and standardized manner, enhancing international recognition and allocation efficiency of Chinese assets through innovative product design and shared international channels [2]